Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Grabbe

Showing results (291-300 of 325) with videos related to

Pageof 33
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 17, 2023
S2k-Leitlinie - Merkelzellkarzinom - Update 2022Jürgen C Becker, Ambros J Beer, Viola K DeTemple, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 InhibitionMax Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.
ACS Nano|February 1, 2022
Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against TumorsJudith Stickdorn, Lara Stein, Danielle Arnold-Schild, et al.
British Journal of Cancer|February 14, 2018
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patientsMarkus Hecht, Friedegund Meier, Lisa Zimmer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 10, 2018
S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86)Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 12, 2017
S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 1: Klassifikation und Diagnostik (ICD10 C82 - C86)Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Cancers|June 2, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg StudyHenner Stege, Maximilian Haist, Michael Schultheis, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 28, 2017
S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86)Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 2, 2017
S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 1: Classification and Diagnosis (ICD10 C82 - C86)Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 21, 2022
S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Pageof 33

Showing results (291-300 of 325) with videos related to

Sort By:
Pageof 33
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 17, 2023
S2k-Leitlinie - Merkelzellkarzinom - Update 2022Jürgen C Becker, Ambros J Beer, Viola K DeTemple, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 InhibitionMax Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.
ACS Nano|February 1, 2022
Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against TumorsJudith Stickdorn, Lara Stein, Danielle Arnold-Schild, et al.
British Journal of Cancer|February 14, 2018
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patientsMarkus Hecht, Friedegund Meier, Lisa Zimmer, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 10, 2018
S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86)Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 12, 2017
S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 1: Klassifikation und Diagnostik (ICD10 C82 - C86)Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Cancers|June 2, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg StudyHenner Stege, Maximilian Haist, Michael Schultheis, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 28, 2017
S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86)Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 2, 2017
S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 1: Classification and Diagnosis (ICD10 C82 - C86)Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 21, 2022
S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Pageof 33